Entrada Therapeutics, Inc.

NASDAQ:TRDA

Biotechnology

Healthcare
$5.03 +0.37%

+$0.03 today

Market cap
$196.93M
Beta
-0.26
P/E (TTM)
-1.7
EPS (TTM)
-$3.97
52W Low $4.93High $16.45

Volume 0.82M

Average 0.36M

TRDA Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Entrada Therapeutics, Inc.NASDAQ: TRDA

Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026

Deferred revenue falls 81.2% from a year ago

Deferred revenue stood at $254K at the end of Q1 FY2026, down 81.2% from a year earlier and down 25.7% from the prior quarter.

Context

  • Deferred revenue amounted to 0.1% of total assets at the end of Q1 FY2026, down 0.2 pp from a year earlier.
  • Deferred revenue increased in 1 of the last 3 fiscal years.

What to watch

Whether deferred revenue keeps falling in the next quarterly balance sheet after a -81.2% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$254K-25.7% QoQ
Last fiscal yearDec 2025
$342K-97.5% YoY
Year agoMar 2025
$1.35M-81.2% since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-81.2%——
1 year-97.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
342K USD
Year-over-year change
-97.5%

Deferred Revenue vs competitors

How TRDA compares with its peers on the latest reported figures

  • TRDA's Mar 2026 deferred revenue of $254K is the 4th highest of the 11 companies compared; the peer median is $0.
  • Its year-over-year change of -81.2% is the 3rd highest of 4, against a peer median of -49.6%.
  • Deferred revenue amounts to 0.1% of total assets for TRDA, versus a peer median of 0.0%.
TRDA Competitors Peer median
Deferred Revenue for TRDA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CAPRCapricor Therapeutics, Inc.Mar 2026$12M +0.0%-12.6%3.7%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$7.61M -49.6%-38.9%3.1%
VYGRVoyager Therapeutics, Inc.Mar 2026$395K -98.1%-70.1%0.2%
TRDAEntrada Therapeutics, Inc.Mar 2026$254K -81.2%—0.1%
ACHVAchieve Life Sciences, Inc.Mar 2026$0 ——0.0%
AVIRAtea Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
SGMTSagimet Biosciences Inc.Mar 2026$0 ——0.0%
ALLOAllogene Therapeutics, Inc.Mar 2026$0 ——0.0%
VNDAVanda Pharmaceuticals Inc.Mar 2026$0 ——0.0%
IMRXImmuneering CorporationMar 2026$0 ——0.0%
HUMAHumacyte, Inc.Mar 2026$0 ——0.0%
Peer median (excluding TRDA) $0-49.6%-38.9%0.0%

Competitors are the stored peer set for TRDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents291.06M45.16M67.6M101.21M90.39M
Short-term Investments0143.56M284.37M318.79M205.3M
Net Receivables005.88M3.68M2.58M
Inventory00000
Other Current Assets021.16M11.92M16.36M7.98M
Total Current Assets298.7M209.88M369.77M440.04M306.25M
Property, Plant & Equipment (Net)6.26M33.02M92.68M82.05M67.76M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets872K9.16M6.74M4.23M3.36M
Total Non-current Assets7.13M42.18M99.42M86.28M71.13M
Total Assets305.83M252.06M469.19M526.32M377.38M
Account Payables706K5.99M3.28M4.26M2.29M
Short-term Debt00000
Tax Payables004.02M667K0
Deferred Revenue00132.26M13.65M342K
Other Current Liabilities4.56M5.49M7.66M8.43M9.22M
Total Current Liabilities6.72M21.97M158.8M39.48M24.45M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)007.72M6.51M0
Other Non-current Liabilities396K0000
Total Non-current Liabilities396K17.53M68.04M58.16M46.79M
Total Liabilities7.12M39.5M226.83M97.64M71.25M
Common Stock3K3K3K4K4K
Retained Earnings(93.67M)(188.29M)(194.97M)(129.34M)(273.09M)
Accumulated OCI0(2.06M)195K(43K)652K
Other Stockholders Equity00000
Minority Interest00000
Total Equity298.72M212.55M242.36M428.68M306.13M
Total Debt025.94M68.23M59.21M50.93M
Net Debt(291.06M)(19.22M)628K(42M)(39.46M)

Entrada Therapeutics, Inc.

NASDAQ:TRDA

Intrinsic Alpha fair value

Locked

Current Price

$5.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.